Skip to main content
OpenTrials
Completed

NCT Number: NCT01885572

National, Multicenter PMS Study "Patient Reported Outcome" in Breast Reconstruction Following Mastectomy With TiLOOP Bra

This multicentre, non-randomised, observational clinical device investigation will be performed to obtain postmarketing information on the TiLOOP® Bra and in particular on the improvement of the patients' quality of life as well as on the rate of complications of the device under investigation.

The objective of this clinical investigation is to establish the feasibility, efficacy and safety of the TiLOOP® Bra.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Charite Campus Mitte and Benjamin Franklin, Berlin, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

The TiLOOP®Bra is designed to assist oncologically indexed skin sparing mastectomy or subcutaneous mastectomy with preservation of the nipple-areola-complex during primary breast reconstruction, secondary breast reconstruction or corrective breast surgery. Patients shall be included if they meet all of the following criteria:

Clinical Criteria (reason):

  • women with indication of prophylactic operation or oncoplastic operation with support of a mesh implant
  • women with histologically confirmed breast cancer or precancerosis or genetic pre-existing conditions with increased risk of breast cancer or with a family history
  • the health of women must comply with ECOG (Eastern Cooperative Oncology Group) performance status 0-2

Study-related inclusion criteria - Legal reasons:

  • Patient is mentally able to understand the nature, aims, or possible consequences of the clinical investigation
  • Patient information has been handed out and all written consents are at hand.
  • Patient is between 18 and 70 years old.

Exclusion criteria

Patients must be excluded if any of the following conditions exist or cannot be excluded:

Device-related exclusion criteria (contraindications):

Pathological or physical condition precluding such as:

  • Pregnancy or breast-feeding patients
  • Known intolerance to the mesh-implants under investigation.

Study-related exclusion criteria - Medical reasons:

  • metastatic breast cancer
  • medicamentous regulated diabetes with blood sugar level >250
  • inadequate bone marrow function with neutrophil granulocytes <1500 and blood plates < 10000/µl
  • patient with known contraindication to mesh-implants or plastic-reconstructive breast operations

Study-related exclusion criteria - Legal reasons:

  • Lack of written patients informed consent.
  • Lack of patient compliance regarding data collection, treatment or follow-up investigations in the scope of the protocol.
  • Patient is institutionalized by court or official order (MPG§20.3).
  • Participation in another operative clinical investigation.

It is thought that the study-related exclusion criteria will not significantly influence the sample of the population under investigation.

Treatment and study plan

TiLoop Bra

Device

Titaniferously coated polypropylene mesh

Primary outcomes

  1. PRO

    Time frame: 12 months after breast reconstruction

    Measurement of the Patient Reported Outcome (PRO).

Secondary outcomes

  1. PRO

    Time frame: 6 and 24 months after breast reconstruction

    Measurement of the Patient Reported Outcome

  2. Complication Rate

    Time frame: after 6, 12 and 24 months

    Complication rate of the first 60 patients in the 6 month follow-up and of all patients after 6, 12 and 24 months.

  3. Cosmetic Success

    Time frame: 6, 12 and 24 months after breast reconstruction

    Cosmetic success confirming the reinforcement will be assessed by the patient and an independent professional at a photo. The questions posed are part of the validated Breast Q questionnaire.

  4. PRO and Complication Rate

    Time frame: 48 months after breast reconstruction

    Measurement of the Patient Reported Outcome and complication rate of all patients

Sponsors and collaborators

Lead sponsor

Pfm Medical Mepro Gmbh

Industry

Collaborators

  • pfm medical gmbh

Registry information

Official study title

National, Multicenter Post-market Surveillance Study "Patient Reported Outcome" in Breast Reconstruction Following Mastectomy With Titaniferously Coated Polypropylene Mesh (TiLOOP Bra)

Acronym: PRO-BRA

Important dates

Study start
2013
Primary completion
2017
Study completion
2021
First posted
Jun 25, 2013
Registry last updated
Sep 20, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.